טוען...
Targeting CD20: teaching an old dog new tricks
Rituximab was the first monoclonal antibody used for the treatment of a malignancy. In the 22 years since initial approval, it has become a vital component of therapy for a multitude of B-cell malignancies. Within the last several years, however, there has been a robust development of novel agents t...
שמור ב:
| הוצא לאור ב: | Hematology Am Soc Hematol Educ Program |
|---|---|
| מחבר ראשי: | |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Society of Hematology
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6913507/ https://ncbi.nlm.nih.gov/pubmed/31808844 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2019000031 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|